dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination has been researched along with indomethacin in 2 studies
| Studies (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Trials (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Recent Studies (post-2010) (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Studies (indomethacin) | Trials (indomethacin) | Recent Studies (post-2010) (indomethacin) |
|---|---|---|---|---|---|
| 219 | 84 | 3 | 29,527 | 1,838 | 3,396 |
| Protein | Taxonomy | dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination (IC50) | indomethacin (IC50) |
|---|---|---|---|
| Chain A, membrane-associated prostaglandin E synthase-2 | Macaca fascicularis (crab-eating macaque) | 1000 | |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | 1.1 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.9994 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.7764 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.34 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5605 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.004 | |
| Interleukin-8 | Homo sapiens (human) | 0.05 | |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.004 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 6 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 5 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 0.011 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.4848 | |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | 0.2 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.1 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.082 | |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | 4.5 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 5.7 | |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | 0.2 | |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | 0.2 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 1.5128 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.5504 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 3.4486 | |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | 0.2 | |
| C-X-C chemokine receptor type 3 | Homo sapiens (human) | 0.05 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 8.97 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.4647 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.4233 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 3 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.49 | |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | 7.7 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.5461 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.96 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Autret, E; Laugier, J; Nasr, C; Saliba, E; Suc, AL | 1 |
| Carlos, RQ; Davonzo, C; Dimaguila, MA; Gal, P; McPherson, C; Ransom, JL; Smith, M; Wimmer, JE | 1 |
2 other study(ies) available for dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination and indomethacin
| Article | Year |
|---|---|
Perinatal pharmacology and cerebral blood flow.
Topics: Arteries; Blood Flow Velocity; Caffeine; Carbon Dioxide; Cerebrovascular Circulation; Drug Combinations; Fatty Alcohols; Humans; Indomethacin; Infant, Newborn; Partial Pressure; Phenobarbital; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfactants | 1992 |
Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Biological Products; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Interactions; Ductus Arteriosus, Patent; Echocardiography; Echocardiography, Doppler, Color; Fatty Alcohols; Guideline Adherence; Humans; Indomethacin; Infant, Newborn; Intensive Care Units, Neonatal; Kidney; Metabolic Clearance Rate; Phosphorylcholine; Polyethylene Glycols; Prospective Studies; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn | 2010 |